Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Newron Pharmaceuticals

Newron Pharmaceuticals?uq=w9if130k
1999 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
NWRN STOCK SYMBOL
2 INVESTMENTS
$11.03 SHARE PRICE (As of Friday Closing)
Description

Provider of bio pharmaceutical products intended to develop novel therapies for diseases of the central nervous system (CNS) and pain. The company's bio pharmaceutical products are used in treatments for rare disease and are at various stages of clinical development enabling patients avail treatment on specific rare pain indications.

Website
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Stock Exchange
SWX
Primary Office
  • Via Ludovico Ariosto 21
  • Bresso
  • 20091 Milan
  • Italy

+39 02 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Newron Pharmaceuticals’s full profile, request a free trial.

Newron Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$8.64 - $19.12 $191M $10.73 -$0.33 45.5K 17.8M

Newron Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
FY 2014
31-Dec-2014
Enterprise Value 269,720 233,084 324,312 315,642
Revenue 15,803 7,440 2,640 2,065
EBITDA (5,294) (16,899) (27,772) (14,322)
Net Income (5,383) (16,854) (25,310) (13,391)
Total Assets 65,581 59,517 48,521 45,083
Total Debt 208 383 794 1,322
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Newron Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Newron Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Newron Pharmaceuticals Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 13-Jun-2012 000000000000000000 000.00 Therapeutic Devices
Hunter-Fleming 29-Apr-2008 Merger/Acquisition 00.000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Newron Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Newron Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Newron Pharmaceuticals Executive Team (5)

Name Title Board
Seat
Contact
Info
Stefan Weber Chief Executive Officer, Board Member & Managing Director
Dennis Dionne Executive Director of Commercial Operations
Marco Caremi Executive Vice President, Business Development
Roberto Galli Vice President, Finance
Ravi Anand Chief Medical Officer

Newron Pharmaceuticals Board Members (8)

Name Representing Role Since Contact
Info
000000 000000000 00.0 Self Board Member 000 0000
0000000 00000000 00.0 Self Chairman of the Company's Audit and Risk Committee and member of the Compensation and Nomination Com 000 0000
000000 0000000 00.0 Self Non-Executive Board Member 000 0000
000000 0000000 00 Newron Pharmaceuticals Chairman 000 0000

4 Former Board Members

You’re viewing 4 of 8 board members. Get the full list »